| Libby M Brever, MD | |
|
30 Railroad Ave, Albany, MN 56307-9379 | |
| (320) 845-2157 | |
| (320) 845-6138 |
| Full Name | Libby M Brever |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 30 Railroad Ave, Albany, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649447715 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 52115 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centracare Health Home Care | Saint cloud, MN | Home health agency |
| Centracare Health Hospice | Saint cloud, MN | Hospice |
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Centracare Health System - Melrose Hospital | Melrose, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centracare Clinic | 2466363395 | 632 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20060504000839 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Entity Name | Centracare Health System - Sauk Centre |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578813762 PECOS PAC ID: 4981857216 Enrollment ID: O20130116000380 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Entity Name | Centracare Health System - Sauk Centre |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740553932 PECOS PAC ID: 4981857216 Enrollment ID: O20140523001292 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Libby M Brever, MD 30 Railroad Ave, Albany, MN 56307-9379 Ph: (320) 845-2157 | Libby M Brever, MD 30 Railroad Ave, Albany, MN 56307-9379 Ph: (320) 845-2157 |
News Archive
Patient satisfaction after plastic surgery is most affected by surgeon-related factors, such as taking the time to answer questions and including patients in the decision-making process, reports a study in the September issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A solid tumor can cause muscle cells in the body to self-destruct. Many cancer patients die from the consequences. Now researchers are discovering more about how cancer cells in a tumor can take control of muscle cell wasting and trigger a chronic, serious condition.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
› Verified 1 days ago
Daron W Gersch, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 3rd Ave, Albany, MN 56307 Phone: 320-845-2157 Fax: 320-845-6138 | |
Charlene Ann Gerner, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 3rd Avenue, Centracare Clinic Albany, Albany, MN 56307 Phone: 320-845-2157 Fax: 320-845-6138 | |
Earl T Kinnear, SFNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 3rd Ave, Albany, MN 56307 Phone: 320-845-2157 Fax: 320-845-6138 | |
Dr. Nathan R Brever, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 3rd Avenue, Centracare Clinic - Albany, Albany, MN 56307 Phone: 320-845-2157 Fax: 320-845-6138 | |
Dr. Brittany Nagel, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Railroad Ave, Albany, MN 56307 Phone: 320-845-2157 |